Expired
Lead Plaintiff Deadline
Apr 9, 2024
Choose your preferred way to stay informed of new case launches and settlement deadlines
The filed complaint alleges that Amylyx Pharmaceuticals, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) defendants had overstated commercial prospects RELYVRIO, a dual UPRBax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the U.S.; (ii) patients were discontinuing treatment with RELYVRIO after six months; (iii) the rate at which new patients were starting treatment with RELYVRIO was decreasing; (iv) accordingly, defendants had also overstated RELYVRIO’s prescription rate; (v) defendants attempted to hide the foregoing negative trends from investors and the market by blocking analysts from viewing RELYVRIO’s prescription data; and (vi) as a result, defendants’ public statements were materially false and misleading at all relevant times.
In order to be eligible to join the AMLX class action lawsuit, you must have incurred a loss on shares of Amylyx purchased during the class period listed above.
If you suffered a loss in Amylyx during the relevant time frame or pursuant to the relevant offering(s), you have until April 9, 2024 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
TOP
